Stockwinners Market Radar for March 11, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:10 EDT Cathie Wood's ARK Investment bought 2.5M shares of SoFi Technologies today

20:09 EDT Cathie Wood's ARK Investment bought 314K shares of Pinterest today

19:50 EDT LM Funding America trading halted, news pending

18:46 EDT Alcoa enters binding agreement to acquire Alumina Limited in all-stock deal - Alcoa announced that it has entered into a binding Scheme Implementation Deed with Alumina Limited, under which Alcoa will acquire Alumina Limited in an all-scrip, or all-stock, transaction. The Agreement terms are consistent with the previously agreed and announced transaction process deed. Consistent with the Process Deed, the Alumina Limited Board of Directors has recommended that Alumina Limited shareholders vote in favor of the Agreement in the absence of a superior proposal and subject to an independent expert concluding that the transaction is in the best interests of Alumina Limited shareholders. The Independent Directors of Alumina Limited, and its Managing Director and Chief Executive Officer intend to vote all shares of Alumina Limited held or controlled by them in favor of the Agreement. The terms of the Agreement are consistent with the Process Deed. Accordingly, under the Agreement, Alumina Limited shareholders would receive consideration of 0.02854 Alcoa shares for each Alumina Limited share. Upon completion of the transaction, Alumina Limited shareholders would own 31.25%, and Alcoa shareholders would own 68.75% of the combined company. Based on Alcoa's closing share price as of February 23, 2024, the last trading day prior to the announcement of the Process Deed, the Agreed Ratio implies a value of A$1.15 per Alumina Limited share and an equity value of approximately $2.2B for Alumina Limited. As part of the Agreement, interests in Alcoa shares would be delivered in the form of CHESS Depositary Interests that represent a unit of beneficial ownership in a share of Alcoa common stock, which would allow Alumina Limited shareholders to trade Alcoa common stock via CDIs on the Australian Stock Exchange. In order to allow the trading of Alcoa CDIs, Alcoa will apply to establish a secondary listing on the Australian Securities Exchange. Alcoa has committed to maintain the CDI listing for at least 10 years. In addition, two new mutually agreed upon Australian directors from Alumina Limited's Board would be appointed to Alcoa's Board of Directors upon closing of the transaction. Under the terms of the Agreement and at Alumina's request, Alcoa has agreed to provide short-term liquidity support to Alumina Limited to fund equity calls made by the AWAC joint venture if Alumina Limited's net debt position exceeds $420 million. Based on AWAC's current 2024 cashflow forecast, Alcoa does not expect any support to be required in the 2024 calendar year. Subject to certain accelerated repayment triggers, Alumina Limited would be required to pay its equity calls (plus accrued interest) not later than September 1, 2025 in the event the transaction is not completed. Allan Gray Australia, currently the largest substantial holder in Alumina Limited, has confirmed it continues to be supportive of the proposed transaction. The transaction is expected to be completed in the third quarter 2024, subject to the satisfaction of customary conditions as well as approval by both companies' shareholders and receipt of required regulatory approvals. The required regulatory approvals include approvals from Australia's Foreign Investment Review Board and from the antitrust regulators in Australia and Brazil. The transaction is not conditional on due diligence or financing.

18:18 EDT Assure Holdings to sell certain assets to MPOWERHealth for up to $4.5M - Assure Holdings Corp. announced that it has entered into an agreement to sell certain assets of its IONM business to MPOWERHealth for up to $4.5M, of which $2.5M will be paid in cash at the initial closing and up to an additional $2M to be paid in relation to a potential earnout payment tied to case volume from the acquired assets during the 12-month period following the initial closing. The asset sale includes most of the Company's healthcare facility contracts and clinical equipment, and a majority of the Company's employees. The Company retains certain of its assets, including but not limited to, its accounts receivable and its employees in the revenue cycle management team. The initial closing of the sale of assets is subject to certain customary closing conditions and consents. The Company expects that the initial closing will occur on or around March 22, 2024. John Farlinger, Assure's executive chairman and CEO, commented, "The sale of IONM assets to MPOWER provides Assure with a clear pathway to meet its strategic objective of repurposing our business and closing our merger with Danam Health. We are pleased that MPOWER will continue providing our surgeon partners with the high-quality IONM services they are accustomed to receiving using the same neurophysiologists they work with today."

17:38 EDT Acushnet Holdings exec sells $1.09M in common stock - In a regulatory filing, Acushnet Holdings disclosed that its Titleist Golf Gear President John Duke sold 17K shares of common stock on March 8th as part of an option exercise in a total transaction size of $1.09M.

17:11 EDT Reinsurance Group CFO Larson sells 3,750 common shares - In a regulatory filing, Reinsurance Group CFO Todd Larson disclosed the sale of 3,750 common shares of the company on March 8 at a price of $181.26 per share.

17:03 EDT Ferroglobe, Coreshell sign MoU over silicon for EVs - Ferroglobe announced the signature of a memorandum of understanding. Together, Ferroglobe and Coreshell expect to produce the first battery-ready metallurgical silicon for the development of low-cost, high-range EV batteries in compliance with the U.S. Inflation Reduction Act. The partnership will enable the leapfrogging of silane-based silicon and the replacement of graphite in EV batteries, which have bottlenecked the auto industry since the introduction of electric vehicles, creating cost and range limitations. Electric vehicles suffer from significant cost disadvantages for consumers and automakers alike, with batteries comprising 30-40% of the total cost of electric cars. Car manufacturers are interested in using silicon in batteries because it can store up to 10 times more energy in the anodes than graphite. This could potentially result in a 30 percent increase in driving range. Coreshell's proprietary battery technology, featuring a unique nanomaterial electrode coating, is the only proven solution to mitigate the degradation of micrometric silicon, preventing its rapid loss of life while still allowing lithium ions to pass through. Ferroglobe's proprietary metallurgical purification process to produce up to 99.995% silicon is cost-effective and does not use any chemical reagent, a key technology for producing affordable silicon active material. These innovations enable, for the first time, the development of lithium-ion batteries with metallurgical silicon dominant anodes that meet product requirements for lifetime across a range of applications. "We believe battery-grade, micrometric silicon is the fastest path to decarbonizing the mobility industry," said Benoist Ollivier, Chief Technology & Innovation Officer of Ferroglobe. "When the right battery technology partner and the leading supplier of silicon to the U.S. come together, breakthroughs can happen. Coreshell is a leading technology company that has been able to solve the raw metallurgical silicon degradation problem and unlock the true performance of this element. We are thrilled to partner with the battery material innovators at Coreshell and play our part in accelerating the transition to clean energy in the automotive industry for everyone."

17:01 EDT Rumble announces public launch of Rumble Cloud - Rumble announced the public launch of Rumble Cloud, a new infrastructure as a service offering that "champions the free and open internet." "The cloud market is desperate for real competition that isn't controlled by an oligopoly. Our cloud will bring top network speed and quality, but most importantly, we plan to disrupt the market with our pricing strategy," said Rumble Chairman and CEO Chris Pavlovski. "Just as our video platform has taken market share away from YouTube, we plan to do the exact same in the cloud market that Amazon, Google, and Microsoft have cornered," he added.

16:59 EDT Group 1 Automotive acquires Modern Classic Motors in Hilton Head, SC - Group 1 Automotive announced the acquisition of Modern Classic Motors in Hilton Head, South Carolina. The acquisition includes three franchises: Mercedes-Benz, Sprinter and Honda in Beaufort County, one of the fastest-growing counties in South Carolina. The acquisition expands Group 1's relationship with Mercedes-Benz to 17 franchises in the U.S. and U.K. and with Honda to 13 franchises in the U.S. The dealerships are expected to generate $140M in annual revenues. Group 1's President and CEO Daryl Kenningham stated, "We are delighted to grow our relationship with Mercedes-Benz and Honda while adding scale to our successful Hilton Head operations with these highly desirable brands." Group 1 has now acquired an estimated $1B of annual revenues in 2024, which follows $1.1B of acquired revenues in 2023.

16:53 EDT Best Buy founder sells $19.36M in common stock - In a regulatory filing, Best Buy disclosed that its founder Richard Schulze sold 242K shares of common stock on March 8th in a total transaction size of $19.36M.

16:37 EDT Vail Resorts reports certain ski season metrics through March 3 - The company reported certain ski season metrics for the comparative periods from the beginning of the ski season through March 3, 2024, and for the prior year period through March 5, 2023. The reported ski season metrics are for the company's North American destination mountain resorts and regional ski areas, excluding the results of the Australian ski areas and Andermatt-Sedrun in both periods. Season-to-date total skier visits were down 9.7% compared to the prior year season-to-date period. Season-to-date total lift ticket revenue, including an allocated portion of season pass revenue for each applicable period, was up 2.6% compared to the prior year season-to-date period. Season-to-date ski school revenue was up 5.5% and dining revenue was down 0.5% compared to the prior year season-to-date period. Retail/rental revenue for North American resort and ski area store locations was down 9.3% compared to the prior year season-to-date period. Commenting on the season-to-date metrics, Lynch said, "Across our North American resorts, unfavorable conditions negatively impacted season-to-date visitation, which was below both prior year levels and our expectations based on the number of guests visiting and their frequency. Following the Martin Luther King Jr. holiday weekend, challenging conditions persisted until early March at Whistler Blackcomb and our Tahoe resorts, and while conditions improved at our Rockies and Eastern resorts, visitation did not improve as quickly as expected. We expect a portion of the lower visitation is related to the challenging conditions in the first half of the season as well as a shift in visitation patterns. Despite the decline in season-to-date visitation relative to the prior year period, we are pleased with lift revenue growth driven by the stability created from the season pass program, the strength in ancillary spending per skier visit across our ski school, dining, and rental businesses, and the improving trends as the season progresses."

16:35 EDT Acadia trading resumes

16:31 EDT Eli Lilly CAO Zakrowski sells 750 common shares - In a regulatory filing, Eli Lilly CAO Donald Zakrowski disclosed the sale of 750 common shares of the company on March 11 at a price of $753.60 per share.

16:27 EDT Talos Energy sees FY24 upstream CapEx $570M-$600M

16:26 EDT Larimar Therapeutics doses first patient in nomlabofusp study - Larimar Therapeutics announced dosing of the first patient in an open label extension, or OLE, study evaluating 25 mg daily subcutaneous injections of nomlabofusp in participants with Friedreich's ataxia, or FA. Nomlabofusp is a novel protein replacement therapy designed to address the root cause of Friedreich's ataxia by delivering frataxin to mitochondria.

16:25 EDT Oracle jumps 6% to $121.68 after reporting Q3 results

16:22 EDT ICF International awarded new $25M contract by Entergy Arkansas - ICF was recently awarded a new three-year, $25M contract by Entergy Arkansas to implement the utility's energy efficiency and demand response program portfolios, as required by the Arkansas Public Service Commission. The contract was awarded in the fourth quarter of 2023.

16:21 EDT Cohen & Steers reports preliminary AUM $79.6B as of February 29 - An increase of $333M from assets under management at January 31. The increase was due to market appreciation of $1.2B, partially offset by net outflows of $683M and distributions of $155M.

16:20 EDT AllianceBernstein reports preliminary AUM $745B as of February 29 - Up from $726B at the end of January. The 3% increase in month-end AUM was driven by market appreciation coupled with positive net flows across all channels, led by Retail.

16:17 EDT Invesco reports preliminary AUM $1.63T as of February 29 - Invesco reported preliminary month-end assets under management of $1.63T, an increase of 3.0% versus previous month-end. The firm delivered net long-term inflows of $1.8B in the month.

16:17 EDT Acadia Pharmaceuticals to resume trading at 4:35pm ET - Acadia Pharmaceuticals is scheduled to resume trading at 4:35 pm ET, with quotation set to resume at 4:30 pm ET, according to Nasdaq. Shares had been halted, news pending, as the company announced that its phase 3 Pimavanserin study in negative symptoms of Schizophrenia did not meet its primary endpoint.

16:13 EDT Acadia Pharmaceuticals says phase 3 Pimavanserin study did not meet endpoint - Acadia Pharmaceuticals "announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 total score. The safety and tolerability profile of pimavanserin was consistent with previous clinical trials, showing a low rate of adverse events. ADVANCE-2 was a 26-week double-blind, randomized, placebo-controlled study of 34 milligram pimavanserin in 454 adult patients with predominant negative symptoms of schizophrenia who had achieved control of positive symptoms with their ongoing antipsychotic treatment. ADVANCE-2 used the NSA-16 scale, designed to measure change on the wide range of predominant negative symptoms that patients experience, which looks at 16 different items in five subscales and covers symptoms such as blunted affect, poor socialization and lack of motivation. The change from baseline observed in the pimavanserin arm of ADVANCE-2 was similar to the change from baseline observed at the 34 milligram dose in ADVANCE-1 (-11.8 vs. -11.6); however, the placebo effect in ADVANCE-2 was higher than the placebo effect observed in ADVANCE-1". CEO Steve Davis states: "We are disappointed the trial did not meet its primary endpoint given the significant unmet need in patients with negative symptoms of schizophrenia. We will continue to analyze these data with our scientific advisors, but we do not intend to conduct any further clinical trials with pimavanserin. We want to thank the patients, their families, and the investigators for their contributions in this important study."

16:11 EDT Alto in LOI with Vault 'to Advance Carbon Capture and Storage initiative' - Alto Ingredients announced that it has entered into an exclusive nonbinding letter of intent and is nearing the execution of definitive agreements to develop a carbon capture and storage CCS project with Vault 44.01 Vault at Alto's Pekin campus in Pekin, IL. The letter of intent provides that Alto will install equipment to capture carbon dioxide CO2 generated from the ethanol production process at its Pekin campus and Vault will safely transport and permanently store the emissions deep underground in a secure geologic reservoir located in close proximity to the campus. The project is intended to substantially reduce CO2 emissions from the ethanol production process and provide direct value to the surrounding communities. Both Alto and Vault continue to engage with local stakeholders, landowners, and communities regarding the project. "Nearing a key milestone in developing this CCS project, Vault looks forward to working with Alto and continuing to work with communities and landowners in the Pekin area to develop a safe and high-quality project. This project with Alto exemplifies our view that one of the best options for CCS is often a local solution," said Scott Rennie, President and Chief Executive Officer of Vault 44.01.

16:10 EDT Virtus Investment reports February AUM of $176.1B vs. $171.1B last month

16:07 EDT Oracle reports Q3 Total Remaining Performance Obligations up 29% to $80B

16:06 EDT Koru Medical announces feasibility study for rare disease therapy - The company states: "KORU Medical announced a collaboration with a global pharmaceutical manufacturer to initiate a feasibility study with KORU's Freedom Infusion System for an already commercialized rare disease therapy. Upon successful completion of the feasibility study, KORU Medical intends to develop a customized Freedom System that will deliver this large volume therapy via subcutaneous administration. Healthcare providers administer this rare disease drug in the growing ambulatory infusion center and ambulatory infusion suite setting in the United States and the hospital setting in the European Union."

16:03 EDT Franklin Resources reports February AUM $1.62T - Franklin Resources "reported preliminary month-end assets under management of $1.62T at February 29, 2024, compared to $1.60T at January 31, 2024. This month's increase in AUM reflected the impact of positive markets and long-term net inflows inclusive of the previously disclosed $5.5 billion in the retirement channel, partially offset by a fixed income institutional client redemption of $2.0 billion."

15:49 EDT FDA reports Abbott recalls HeartMate Touch Communication System - Abbott is recalling their HeartMate Touch System (version 1.0.32) for risk of unexpected pump stop or start. There are 1,560 devices recalled in the U.S. and this recall is "a correction, not a product removal," the FDA noted. Reference Link

14:31 EDT Avangrid announces construction of fifth wind farm in Illinois - Avangrid announced the construction of what will be the company's fifth wind farm in Illinois. Osagrove Flats, located in La Salle County, will include 34 wind turbines with a total capacity of 153 MW. "Avangrid has a long track record of successfully partnering with Illinois communities to build and operate wind farms, helping accelerate a clean energy transition in the state and across the country," said Pedro Azagra, Avangrid CEO. "We are excited to build on our more than 15-year history in Illinois with Osagrove Flats, which will bring jobs and additional investment to the local community." The wind farm will produce more than 550,000 MWh of energy in a year, which is the same amount of power used by about 50,000 U.S. homes.

14:30 EDT Ford agrees to pay $365M to settle customs civil penalty claims - Ford Motor has agreed to pay the United States $365M to resolve allegations that it violated the Tariff Act of 1930 by misclassifying and understating the value of hundreds of thousands of its Transit Connect vehicles, the Justice Department announced. The settlement resolves allegations that Ford devised a scheme to avoid higher duties by misclassifying cargo vans. Specifically, the government alleged that from April 2009 to March 2013, Ford imported Transit Connect cargo vans from Turkey into the United States and presented them to U.S. Customs and Border Protection with sham rear seats and other temporary features to make the vans appear to be passenger vehicles. These temporary rear seats were never intended to be, and never were, used to carry passengers. Rather, the government alleged, Ford included these seats and features to avoid paying the 25% duty rate applicable to cargo vehicles. By classifying the vans as vehicles for the transport of passengers, Ford instead paid a duty rate of just 2.5%. The settlement also resolves allegations that, from April 2009 through August 2013, Ford avoided paying import duties by under-declaring to CBP the value of certain Transit Connect vehicles, the DOJ stated. Reference Link

13:51 EDT Warner Bros. Discovery game 'Multiversus' to launch May 28 - Warner Bros. Discovery said that its upcoming free-to-play fighting game "Multiversus" will release on May 28. Reference Link

12:51 EDT Power & Digital Infrstre Aqstn II Corp trading halted, volatility trading pause

12:44 EDT Adlai Nortye Ltd (ADR) trading halted, volatility trading pause

12:03 EDT EzFill signs fuel delivery agreement with two fleet customers - EzFill Holdings has signed fuel delivery agreement with two new fleet customers and has expanded its service of L&W Supply. The new fleet accounts Fuse Specialty Appliance and GFC Crane Consultants are an luxury appliance company and crane inspection company in Miami. The new customers have joined the EzFleet platform. The expansion with L&W Supply includes service to L&W's location in Rockledge.

12:00 EDT Sonida Senior Living rises 23.3% - Sonida Senior Living is up 23.3%, or $4.37 to $23.16.

12:00 EDT L.S. Starrett Co rises 58.8% - L.S. Starrett Co is up 58.8%, or $5.83 to $15.75.

12:00 EDT Genie Energy falls -10.7% - Genie Energy is down -10.7%, or -$2.03 to $16.90.

11:52 EDT A SPAC I Acquisition Corp trading halted, volatility trading pause

11:37 EDT BHG issues letter to senators related to apparent EchoStar accounting fraud - The Buxton Helmsley Group, the New York City-based investment fund manager with financial interests in EchoStar Corporation (SATS), issued an open letter to U.S. Senators Elizabeth Warren and Sheldon Whitehouse, after EchoStar's filing of a Form 10-K with the U.S. SEC on February 29, 2024, which failed to disclose $15B in implicitly admitted equity value overstatement, among other issues. BHG has issued multiple letters to EchoStar's Board of Directors setting forth the apparent ongoing accounting and securities fraud at the Company, and EchoStar has never denied the allegations; instead, EchoStar resorted to stripping assets from DISH Network Corporation shortly after BHG had privately brought DISH's evidenced net asset insolvency to the attention of the EchoStar Board. Simultaneous to the Letter issued to U.S. Senators Warren and Whitehouse, BHG also issued a separate letter to EchoStar's Board of Directors, discussing the Company's continued accounting and securities law failures as part of its February 29 Form 10-K. BHG also addressed verbal statements made by the Company's leadership on its March 1, 2024, earnings call, which further support BHG's allegations of apparent accounting and securities fraud occurring at the Company. As part of the Letter to U.S. Senators Warren and Whitehouse, BHG also mentions its whistleblowing involvement at Mallinckrodt plc (MNK).

10:27 EDT PetVivo terminates ATM sales agreement with ThinkEquity - In a regulatory filing, PetVivo disclosed that the company and ThinkEquity mutually agreed to terminate the ATM sales agreement, dated as of August 23, 2023 between the company and with ThinkEquity as the agent, effective as of March 7. Subject to the terms and conditions of the ATM agreement, the company could from time to time offer and sell shares of the company's common stock having an aggregate offering price of up to $2,500,000 through the agent in "at-the-market offerings" as defined in Rule 415 of the Securities Act of 1933, as amended. Prior to termination, the company issued and sold 674,000 shares of its common stock under the ATM agreement, raising net proceeds of $959,033, the filing noted. Reference Link

10:12 EDT Bitfarms purchases additional miners to reach 21 EH/s in 2024 - Bitfarms exercised its previously announced purchase option for 28,000 Bitmain T21 miners and also purchased an additional 19,280 Bitmain T21 miners for US$14/TH, 3,888 Bitmain S21 miners and 740 Bitmain S21 hydro miners for $17.50/TH.

10:08 EDT Energem Corp trading resumes

10:02 EDT Eagle Pharmaceuticals discloses resignation of CFO Brian Cahill - Eagle Pharmaceuticals disclosed late Friday that Brian Cahill resigned from his position as Chief Financial Officer, effective immediately. The board has instituted a search for Cahill's successor as CFO. Steven Ratoff, a member of the board and Chair of the Audit Committee of the Board, was appointed Interim CFO, Principal Financial Officer and Principal Accounting Officer of the company, effective immediately, to serve until such time as a new CFO commences employment or such other date determined by the board.

10:00 EDT MoneyLion falls -8.5% - MoneyLion is down -8.5%, or -$6.30 to $68.19.

10:00 EDT Huya rises 15.0% - Huya is up 15.0%, or 59c to $4.53.

10:00 EDT L.S. Starrett Co rises 58.7% - L.S. Starrett Co is up 58.7%, or $5.82 to $15.74.

09:48 EDT WaveDancer urges stockholders to vote for proposals ahead of Special Meeting - WaveDancer encourages its stockholders to participate actively by casting their vote now for the upcoming meeting of stockholders on March 14, 2024. The Board of Directors emphasizes the importance of this stockholders' vote, specifically urging a positive vote FOR each proposal contained in the proxy. The Company believes a vote FOR each proposal is important for several reasons: Consummation of the Merger with Firefly Neuroscience is critical in WaveDancer's effort to deliver long-term value to its stockholders. Increased Ability for Potential Fundraising: Stockholder Approval will facilitate the joint effort between WaveDancer and Firefly to conduct a successful fundraising effort to close the transaction. Failure to secure approval for the proposals may hinder management's ability to execute its strategy, potentially forcing consideration of selling company assets at less-than-optimal prices, to the potential detriment of stockholders. A Nasdaq delisting could complicate stockholders' ability to trade our common stock, impacting its price and affecting your ability to buy or sell when desired.

09:48 EDT Ventyx Biosciences trading resumes

09:47 EDT EQT Corporation falls -6.0% - EQT Corporation is down -6.0%, or -$2.26 to $35.26.

09:47 EDT Nuscale Power rises 10.9% - Nuscale Power is up 10.9%, or 60c to $6.09.

09:47 EDT L.S. Starrett Co rises 59.0% - L.S. Starrett Co is up 59.0%, or $5.85 to $15.77.

09:42 EDT Trxade Health Inc trading halted, volatility trading pause

09:41 EDT Bally's up 18% after Standard General offers $15 per share buyout - Shares of Bally's are up $1.89, or 18%, to $12.51 after the investor disclosed its buyout proposal.

09:38 EDT Standard General offers to buy all outstanding Bally's shares for $15 per share - On March 11, Standard General delivered a non-binding letter to the board of directors of the company proposing a transaction under which it would acquire all of the outstanding shares of common stock not currently owned by Standard General at a price of $15.00 per share. A filing states: "Standard General expects that the Board of Directors of the Company will appoint a special committee of independent directors to consider its proposal and make a recommendation to the Board of Directors. Standard General will not move forward with the transaction unless it is approved by such a special committee. In addition, the transaction will be subject to a non-waivable condition requiring the approval of holders of a majority of the shares of the Company not owned by Standard General or parties affiliated with Standard General. No assurances can be given that a transaction will be consummated. The Proposal Letter provides that no legally binding obligation with respect to a transaction will exist unless and until mutually acceptable definitive documentation has been executed and delivered with respect thereto." The filing shows that Standard General owns 23.2% of Bally's shares. Reference Link

09:34 EDT Ballys trading halted, volatility trading pause

09:24 EDT BOS' Intelligent Robotics Division receives EUR 615,000 order - BOS Better Online Solutions announced that its Intelligent Robotics Division has received a EUR 615,000 order for a robotic production line from an Israeli defense-industry customer. This order will be delivered in March 2025.

09:17 EDT Crexendo's NetSapiens Platform chosen to power Reinvent's UC&C offering - Crexendo announced that Crexendo's NetSapiens Platform has been chosen to power Reinvent's next generation white label UC&C offering to its community of reseller partners.

09:14 EDT AbCellera gets upfront payment for collaboration with Biogen for antibodies - AbCellera (ABCL) and Biogen (BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience. "Delivering biologics across the blood brain barrier is one of the most important and long-standing problems in neuroscience," said Murray McCutcheon, Ph.D., SVP, Partnering at AbCellera. "We are excited to work with Biogen on this innovative program, which has the potential to unlock multiple new approaches to treating neurological conditions." Under the terms of the agreement, AbCellera will receive an upfront payment and is eligible to receive additional milestone payments should the research programs achieve certain research, developmental and regulatory milestones. AbCellera is also eligible to receive potential royalties on future net sales of products that result from the collaboration.

09:10 EDT Gryphon Digital Mining produces 52 bitcoin in February - During February, Gryphon earned approximately 52 bitcoin coins while posting a Company record average self-mining hashing power of 911 PH/s and total attributable hashing power of approximately 1.3 EH/s. The month's performance translated into a bitcoin efficiency rating of 57 BTC/EH. "February was a strong month for Gryphon as we achieved all-time highs in our self-mining hashing power while earning bitcoin valued at $2.6 million based on an average BTC price of $49,875 during the month," remarked Rob Chang, the CEO of Gryphon. "With Bitcoin prices now over $60,000 in March, we look forward to enhanced returns as we continue working on our market-leading bitcoin efficiency."

09:09 EDT Hawkins completes acquisition of Industrial Research Corporation - Hawkins has completed the acquisition of Industrial Research Corporation. Industrial Research distributes water treatment chemicals and equipment for its customers in central to northern Louisiana, eastern Texas and southern Arkansas.

09:09 EDT Wolters Kluwer launches enhanced contract management functionality for Legisway - Wolters Kluwer's Legal & Regulatory division has launched new AI-enhanced functionality for Legisway, the company's all-in-one SaaS legal information and contract management solution for corporate legal departments. The new feature accelerates the contract review processes by enabling legal departments to effortlessly query their contracts using advanced natural language processing. Legisway's new querying functionality empowers users to track contractual obligations more efficiently and better manage the legal, reputational, and commercial risks that may affect their business. Today's enhancements also seamlessly integrate into the platform's recently launched Legal Services Portal module - a collaborative 'ticketing' platform that streamlines requests for legal support from non-legal staff. This accelerates validation of new requests, promoting accelerated contract review and seamless collaboration with other teams.

09:06 EDT Sealsq unveils upgrades to INeS solution - SEALSQ unveiled new upgrades to INeS, its Certificate Management Solution, tailored for the IoT domain. These upgrades extend the platform's capabilities in registration, configuration, provisioning, maintenance, and monitoring of IoT devices, enabling seamless integration with major cloud providers including Azure IoT Hub, AWS IoT, and Google Cloud IoT. This integration empowers SEALSQ to offer comprehensive IoT device management services as part of its product suite. This new INeS version is fully integrated with SEALCOIN, which should become available end Q2 2024, and crafted to cater to the burgeoning sectors of the IoT and M2M communication. This groundbreaking token is not just another addition to the crypto ecosystem, but a pivotal force that could redefine how machines interact and transact in a highly interconnected world. The multifaceted applications of SEALCOIN illuminate its potential to transform various industries and streamline people's daily lives. The INeS platform introduces an advanced Device Management feature accessible via a web interface and REST API. This innovation allows customers and developers to automate the management of devices and certificates, seamlessly integrating these processes with the manufacturing pipeline. INeS excels in remotely managing credentials, including the activation, deactivation, revocation, renewal, and secure provisioning (point-to-point secure update) of IoT edge devices and business applications.

09:06 EDT CPUC issues decision on Cal Water's 2021 General Rate Case, Improvement Plan - The California Public Utilities Commission issued a decision on March 7, 2024 on the 2021 General Rate Case and Infrastructure Improvement Plan for California Water Service. The decision marks the end of an extensive review of the utility's water system improvement plans, costs, and rates. The decision adopts a revised version of the alternate proposed decision issued January 24, 2024, and increases adopted revenues for 2023 by approximately $39.2 million, plus an inflation factor yet to be determined, retroactive to January 1, 2023. It also increases revenues by up to approximately $32.2 million for 2024 and $31.7 million for 2025, subject to the CPUC's escalation earnings test and inflationary adjustments. Importantly, the decision authorizes Cal Water to invest approximately $1.21 billion from 2021 through 2024 in water system infrastructure projects that are needed to continue providing safe, reliable water service to customers throughout California. This includes approximately $160 million of infrastructure projects that may be submitted for recovery via the CPUC's advice letter process. The CPUC's decision approves a progressive rate design that is intended to provide budget stability while benefiting low-income and low-water-using customers by significantly decreasing the cost of the first units of water consumed and increasing the percentage of fixed costs that are recovered in the service charge.

09:04 EDT Verisk Analytics launches new accelerators wcPrism, wcNavigator - Verisk announced the launch of two new accelerators, wcPris, and wcNavigator, designed to streamline and enhance workers' compensation claims processing within Guidewire ClaimCenter. These innovative solutions aim to accelerate claims processes in the insurance industry by leveraging advanced analytics and automation to improve efficiency and accuracy in claims management. The wcPrism accelerator offers a smarter and faster way to report mandatory state-level workers' compensation claims. By automating data extraction and conversion processes, the accelerator can help improve the accuracy and timeliness of workers' compensation compliance by: Using a single comprehensive data feed to automate the generation of required data reports based on industry and state specific reporting requirements. Applying the same validations utilized by states and data collection organizations to facilitate timely and accurate reporting. Verisk's second accelerator, wcNavigator, utilizes predictive analytics to detect and manage high-severity workers' compensation claims within Guidewire ClaimCenter. By accurately identifying claim severity as early as the first notice of injury, wcNavigator enables adjusters and claims managers to proactively address potential issues and allocate resources effectively. This advanced solution can help improve claims outcomes by: Accurately assessing claims severity from first notice of loss. Providing alerts for changes in treatment and proactively monitoring prescribed medications.

09:03 EDT Neuraxis announces Highmark BCBS policy coverage - NeurAxis announced receipt of Highmark Blue Cross Blue Shield policy coverage for approximately seven million lives effective April 8, 2024. Highmark BCBS provides coverage in the mid-Atlantic, covering Pennsylvania, Delaware, New York, and West Virginia.

09:02 EDT Transcode Therapeutics, Akribion report progress on CRISPR-derived tech - TransCode Therapeutics reported positive proof-of-concept laboratory studies in human cells, advancing its strategic partnership with Akribion Genomics. Akribion Genomics, a German-based biotechnology start-up, is focused on a CRISPR-derived molecular complex for cancer treatment. TransCode and Akribion are collaborating to develop a technology that combines Akribion's cell-killing G-dase E, a Class 2 CRISPR nuclease, with TransCode's TTX nucleic acid delivery platform. G-dase E has shown encouraging in vitro results in cells but requires an effective delivery vehicle, such as TTX, to reach intended targets in the body. Proof-of-concept studies to date suggest that Akribion's G-dase E ribonucleoprotein complexes could be conjugated to TransCode's TTX delivery platform, suggesting that the drug candidate could be formulated as intended. These studies also indicate that TTX-G-dase E ribonucleoprotein complexes could be taken up by cancer cells, inducing cancer cell death.

08:59 EDT Safe and Green Development launches XENE AI exclusive waiting list - Safe and Green Development announced an update to the previously announced launch of the XENE Home platform. In anticipation of the launch scheduled for the end of March, we are proud to announce the establishment of an exclusive waiting list. This initiative has been created to provide real estate professionals, investors, as well as prospective home buyers and sellers, with early access to the Company's XENE Home platform. The waiting list can be accessed at: https://www.xenehome.com/ The Company plans to introduce continuous advancements in AI technology following the launch. Beginning with AI-assisted listing tools, document interpretation, and image enhancement capabilities, the Company intends to progressively unveil new functionalities that redefine the technological landscape of real estate throughout the year.

08:58 EDT Cemtrex receives $2.1M in orders through AIS subsidiary - Cemtrex has received $2.1 million in new orders through its Advanced Industrial Services subsidiary. These orders, including a $1.6 million order for two relocation projects from a leading printing and graphics company, and a $0.5 million order to remove existing equipment for an engineering and construction company, affirm AIS' commitment to delivering excellence across its service offerings. Scheduled for completion within this fiscal year, these projects will leverage AIS's comprehensive suite of services, including mechanical, electrical, piping, and project management. This approach not only demonstrates AIS's capability to handle complex industrial requirements but also reinforces its position as a preferred partner in the industry. Details of the customers were not provided due to confidentiality agreements in place.

08:55 EDT NewLake Capital Partners raises quarterly dividend 2.5% to 41c per share - On March 8, 2024, the Company's board of directors declared an increase in the first quarter of 2024 dividend to $0.41 per share of common stock, an increase of 2.5% sequentially and 5.1% year over year.

08:52 EDT 1847 Holdings' ICU Eyewear announces expansion of partnerships - 1847 Holdings announced that its subsidiary, ICU Eyewear Holdings, has made significant advancements in its growth strategies expected to be realized throughout 2024. Committed to fostering both immediate and long-term growth, ICU has strategically focused on cultivating opportunities in key channels including Gift, Program, and Sports, alongside a robust emphasis on online sales. These endeavors have borne fruit, notably marked by the successful onboarding of a new chain of hardware stores in February, reaffirming ICU's position as an innovative and forward-thinking eyewear brand. ICU's largest retail partner, one of the largest retailers in the United States notable for its focus on upscale, trend-forward merchandise at lower costs, has unveiled ambitious plans to open 300 new stores. This retail partner's strategic expansion, which will lead to ICU's products being sold from approximately 1900 stores to over 2200 stores, not only underscores ICU's established market foothold, but also sets the stage for sustained growth in the eyewear category and beyond.

08:50 EDT Royalty Management places environmenal surety bonds within operator network - Royalty Management has placed additional environmental surety bonds within its operator network, enabling the Company to receive attractive bonding premiums and fees as part of its negotiated agreements with RMCO's approved operators of its surety business. Additionally, the Company is also evaluating potential additional accretive acquisitions of both environmental surety businesses and certain high-quality portfolios of existing surety bonds in the domestic marketplace. RMCO currently places environmental surety bonds that generate the potential for steady, recurring cash flows to the Company. The Company is seeking expansion into the regulated market of environmental surety bonds, whereby RMCO can maximize value and seek accretive opportunities for its shareholders, whereby the Company can utilize its network of environmental stewards to ensure that any associated bonds are properly protected and remediated, while also ensuring the that the return profile matches the risk profile of each underlying transaction and operation.

08:47 EDT FSD Pharma submits Phase 1b CTA for unbuzzd - FSD Pharma announces the submission of the Company's Clinical Trial Application for a planned Phase-1b clinical trial to Assess the Safety and Efficacy of unbuzzd in Healthy Volunteers in an Induced State of Alcohol Intoxication. This clinical trial application is submitted for review by a human ethics review committee in Australia, a first step to obtain permission to initiate the clinical trial. Recruitment of healthy volunteers to this trial is expected to begin this April, following approval by the HREC.

08:43 EDT Sonnet BioTherapeutics announces safety data from Phase 1b/2a trial of SON-080 - Sonnet BioTherapeutics Holdings announced that the first Phase 1b/2a clinical trial of SON-080 was cleared to proceed to Phase 2 after review by the independent DSMB. This study is being conducted at two sites in Australia in patients with persistent CIPN using a new proprietary version of recombinant human Interleukin-6, which required confirmation of safety before continued development in Phase 2. Many drugs cause peripheral nerve damage; patients with CIPN experience discomfort that can result in persistent, unbearable pain that may limit chemo therapeutic treatment. SB211 is studying a low dose of rhIL-6 that has an amino acid sequence identical to the native molecule. The trial targets serum levels similar to those induced with moderate exercise, which triggers the natural healing of nerves, muscle, and bone. As a pleiotropic cytokine, native IL-6 participates in several physiological processes, including tissue repair, glucose homeostasis, and the innate immune response at lower levels, but it can result in acute pathological inflammation at higher serum levels. Preclinical models of CIPN and DPN show that low dose rhIL-6 has the potential to stimulate nerve regrowth to re-establish normal sensations, thereby reducing pain and normalizing some of the physiological conditions that had deteriorated due to nerve degeneration. Early versions of rhIL-6, including Serono's atexakin alfa and others, have been tested in hundreds of patients with cancer, diabetes, idiopathic aplastic anemia, or in healthy controls, showing a maximum tolerated dose of 10 microgram/kg three times a week. However, fever, nausea, and vomiting were prominent at doses over 2 microgram/kg TIW. Study SB211 was designed in Phase 1b to show safety using lower doses in CIPN with up to about 1 microgram/kg of Sonnet's new version of IL-6 given subcutaneously TIW for twelve weeks. The protocol required DSMB to review the unblinded safety and tolerability of SON-080 in the first nine patients in SB211. While the data is still blinded to the rest of the team and we do not have access to the responses by group, the initial safety profile mimics that seen in prior studies with lower doses of exogenous rhIL-6. The most prominent symptoms in SB211 included injection site reactions that resolved within a few days, as well as fatigue, body aches, or nausea that were mostly mild with some symptoms that were moderate. One patient developed severe fatigue and withdrew from the study after one month. All adverse events were transient and reversible. The DSMB concluded that the symptoms were tolerable in the initial patients and the study could proceed to Phase 2. The unblinded safety data from two dose levels of SON-080 compared to placebo are expected during the second half of 2024.

08:41 EDT Gilead announces expiration of HSR waiting period for CymbaBay tender offer - Gilead Sciences announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 HSR Act with respect to Gilead's cash tender offer for CymaBay Therapeutics, expired at 11:59 p.m. on March 8, 2024. On February 22 Gilead and CymaBay filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice. The expiration of the HSR waiting period satisfies one of the conditions to consummate the tender offer. Other conditions remain to be satisfied, including, among others, a minimum tender of shares of common stock of CymaBay representing a majority of the total number of outstanding shares of common stock of CymaBay. Unless the tender offer is extended, the offer and withdrawal rights will expire at one minute after 11:59 p.m., Eastern Time, on March 21.

08:38 EDT Ballard Power sees FY24 capital spending $50M-$70M - Sees FY24 operating expense $145M-$165M.

08:37 EDT OSI Systems gets $3M order to provide optical sensors for missile systems - OSI Systems announced that its Optoelectronics and Manufacturing division has received an order valued at approximately $3M to supply advanced optical sensors to a leading defense electronics original equipment manufacturer OEM. These high-precision components are designed for integration into sophisticated missile systems. OSI Systems' Chairman and Chief Executive Officer, Deepak Chopra, stated, "This collaboration underscores our commitment to excellence and innovation in defense technologies. We are honored to contribute to the enhancement of global security measures with our optical sensor product

08:36 EDT Journey Medical presents data from Phase 1 trial of DFD-29 - Journey Medical Corporation announces that data from the Phase 1 clinical trial assessing the impact of DFD-29 on the microbial flora of healthy adults were presented at the 2024 American Academy of Dermatology Annual Meeting that took place March 8-12, 2024, in San Diego, CA. The clinical trial also assessed the safety and tolerability of the treatment. The data were presented by Srinivas Sidgiddi, M.D., Vice President, Research & Development of Journey Medical. DFD-29 is being developed for the treatment of rosacea in collaboration with Dr. Reddy's Laboratories Ltd. DFD-29-CD-006 is a multicenter, randomized, double-blind, placebo-controlled, parallel group study that enrolled 60 healthy, adult subjects in a 2:1 randomization between DFD-29 and placebo. Treatment was administered once daily orally over 16 weeks. Microbiological samples were collected from the skin, stool and vagina at multiple timepoints through the study. The study achieved all primary objectives and no significant safety issues were noted during the study. Claude Maraoui, Co-Founder, President, and Chief Executive Officer of Journey Medical, stated, "We are encouraged by the data presented at the AAD meeting as they demonstrate that DFD-29 can be safely used for up to 16 weeks with no significant risk of microbiota suppression or development of resistance. Based on the robust safety and efficacy data seen throughout all of our clinical trials, we believe that DFD-29 has the potential to change the treatment landscape for the millions of patients suffering from rosacea. If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema from rosacea."

08:35 EDT MicroStrategy acquired about 12,000 bitcoins during February 26 to March 10 - In a regulatory filing, MicroStrategy announced that, during the period between February 26 and March 10, MicroStrategy acquired approximately 12,000 bitcoins for approximately $821.7M in cash, using $781.1M of proceeds from a private offering of convertible senior notes and $40.6M of excess cash, at an average price of approximately $68,477 per bitcoin, inclusive of fees and expenses. As of March 10, MicroStrategy, together with its subsidiaries, held an aggregate of approximately 205,000 bitcoins, which were acquired at an aggregate purchase price of approximately $6.91B and an average purchase price of approximately $33,706 per bitcoin, inclusive of fees and expenses.

08:34 EDT LM Funding mines 26.8 bitcoin in February - Bruce M. Rodgers, Chairman and CEO of LM Funding, stated, "We are currently executing on all fronts with 26.8 Bitcoin mined in February alone, bringing our total Bitcoin to over 150 as of the end of February. In addition, the price of Bitcoin has continued to appreciate, as we had anticipated, in advance of the next halving event. In fact, the value of our Bitcoin held at the end of February was over $10.4 million dollars based on an estimated March 8, 2024 BTC price of $68,000, or approximately $4.28 per share after giving effect to our previously announced 1-for-6 reverse stock split that will become effective on March 12, 2024. Given the strength of our balance sheet, we have not had the need to sell any of our Bitcoin holdings to fund our operations. As a result, we believe our buy-and-hold approach, coupled with our infrastructure-light strategy, could continue to drive significant value for shareholders over the coming months as we deploy more Bitmain S21 Antminer machines and increase our deployed Hash Rate." The Company estimates the value of its 153.6 Bitcoin holdings as of February 29, 2024 was approximately $10.4 million as of March 8, 2024, based on an estimated March 8, 2024, BTC price of $68,000.

08:33 EDT Global Mofy Metaverse announces new subsidiary Gauss AI - Global Mofy Metaverse announced the establishment of a new subsidiary, Gauss AI, which will focus on the monetization of artificial intelligence generated content, AI-generated 3D digital assets and synthetic video content creation. The Company's strong belief that it will be successful in these rapidly expanding markets stems from its extensive digital asset library and database, along with its strong track record of innovation and technological advancement. Synthetic video involves the use of AI and computer graphics techniques across numerous industries, including entertainment and media, to produce realistic-looking videos, stunning visual effects, animations, and game development. It enhances efficiency and quality through machine learning algorithms that automate tasks in the video production process, such as editing, color correction, and motion graphics. This evolving technology often involves the creation of computer-generated imagery, and has a wide range of applications in various industries, including entertainment, virtual production, video editing, and more and is becoming routinely used to create advertisements, product promotions, brand campaigns, and more. Gauss AI, the new subsidiary of Global Mofy Metaverse, will specialize in providing advanced AI solutions to customers, fostering content creation by focusing on helping customers achieve greater efficiency, intelligence, and innovation at a reduced cost. Gauss AI plans to invest in its product and technology roadmaps, as it benefits from existing and new opportunities in the digital entertainment industry, which is being transformed by the wider global adoption and implementation of AI. Its main services will include the development of AI content creation and management systems, as well as synthetic video creation.

08:33 EDT Integra LifeSciences launches MicroMatrix Flex - Integra LifeSciences announced MicroMatrix Flex is now available commercially in the U.S. MicroMatrix Flex is a dual-syringe system enabling the convenient mixing and precise delivery of MicroMatrix paste to provide convenient access to hard-to-reach spaces and to help prepare an even wound surface in challenging wound areas.

08:32 EDT GE Vernova, Montana Technologies close 50/50 JV - GE Vernova announced the close of a 50/50 joint venture with Montana Technologies LLC that will incorporate GE Vernova's proprietary sorbent materials into systems that utilize Montana's patented AirJoule dehumidification, air conditioning, and atmospheric water harvesting technology. "As we work to electrify and decarbonize the world, supporting and scaling breakthrough technologies will be critical to the energy transition," said GE Vernova CEO Scott Strazik. "By leveraging the work of our Advanced Research team with Montana's technology, AirJoule represents a strong step forward in reducing energy use and carbon emissions in the air conditioning industry and the future of air-to-water generation." In support of the JV, GE Vernova has made an investment in Montana Technologies, following on recently announced investments from Carrier and the Rice Investment Group. Furthermore, GE Vernova's Advanced Research team will provide support to the JV's R&D function, and GE Vernova's Dr. Bryan Barton will leave GE Vernova to lead the JV as its CEO. GE Vernova continues to work to identify and incubate other advanced technologies to drive similar outcomes.

08:29 EDT Brera Holdings appoints Dicey Perrine as head of U.S. operations - Brera Holdings announced the appointment of Dicey Perrine as the Head of US Operations. This strategic move underscores Brera Holdings' commitment to excellence and growth, particularly in the context of its involvement with women's professional volleyball: in July 2023, the Company completed the acquisition of a majority ownership in the Italian Serie A1 women's professional volleyball team UYBA Volley S.s.d.a.r.l. Ms. Perrine was a member of the UCLA Women's Volleyball team, where she was a starting player for all four years, Team Captain in 2009 and 2010, and won numerous awards including Most Valuable Player in 2010 and Best Newcomer in 2007.

08:27 EDT Acelyrin says Phase 2b/3 trial of izokibep met primary endpoint - ACELYRIN announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis met the primary endpoint of ACR50 at week 16 with high statistical significance. Results from the 160 mg weekly and every other week arms showed improved magnitude of responses on higher hurdle endpoints such as ACR70, PASI100, and Minimal Disease Activity relative to the Phase 2 80 mg Q2W dose. This is notable given a higher baseline disease burden in the Phase 2b/3 trial population relative to the Phase 2 trial. Izokibep was well-tolerated with a favorable safety profile consistent with previous experience and the IL-17A class, without evidence of the safety liabilities observed with targeting IL-17A&F. The trial had a low study discontinuation rate of less than 3%. Mild-to-moderate injection site reactions were observed with discontinuations due to ISR less than 2%. There were two cases of mild candida - one in the placebo arm and one in the 160 mg QW arm - and no cases of suicidal ideation/behavior. Pre-specified analyses continue to support the potential for differentiation in enthesitis resolution. Consistent high magnitude absolute responses were demonstrated in the Phase 2-comparable population although enthesitis resolution overall was not statistically significant due to high placebo response. Izokibep achieved clinically meaningful resolution in patients with the highest burden of enthesitis relative to placebo an effect not previously reported by other agents. Additional information about these results can be found at ACELYRIN.com. Further data from this trial will be presented at future scientific meetings.

08:24 EDT Daxor announces sales to three new hospitals - Daxor announces the expansion of blood volume analysis in three new hospitals through new analyzer purchases, and the utilization of Daxor's ezBVA Lab service. These new acquisitions further fuel BVA sales growth and underscore its clinical relevance. New client and services wins include: BVA analyzer purchase at a 735-bed non-profit, tertiary, research and academic medical center located in northern New Jersey. Daxor's ezBVA Lab service extended to a regional academic medical center, Level I adult trauma center in Ohio. Daxor's ezBVA Lab service extended to an academic, integrated health system located in South Carolina.

08:22 EDT Evolv rejects IPVM's deceptive anddangerous articles - Evolv Technology published this open letter to publication IPVM addressing concerns that IPVM's continuous stream of articles on the Company is not only deceptive, but could pose a danger to the public. Since 2021, IPVM has published approximately 100 articles featuring or referencing Evolv, which are almost uniformly negative in tone. During that same timeframe, Evolv has noted that IPVM seems to have focused less on other companies in the weapons detection industry. Evolv has concerns about IPVM's inaccurate and misleading coverage. Evolv is also concerned about the public safety implications of IPVM's distorted coverage and release of sensitive security information SSI , which can potentially provide a roadmap to bad actors on how to circumvent a security system. Evolv's position is that IPVM is not only biased towards the selective use of misinformation, but also does not reflect subject matter expertise in the physical security industry or advance public safety priorities. The Evolv standard of excellence is consistently tested through its broad client base and expectations of its Security Advisory Board. The Board includes senior leaders who have served at the highest levels of their profession in national security, law enforcement and the United States military. The Security Advisory Board has carefully examined IPVM statements regarding Evolv Technology systems and concludes that IPVM has consistently misrepresented product effectiveness and is irresponsible in their reporting. T

08:22 EDT R1 RCM forms special committee to evaluate strategic alternatives - R1 RCM announced the formation of a special committee comprised solely of independent directors to evaluate strategic alternatives in response to the Schedule 13D/A filed by New Mountain Capital, L.L.C. with the Securities and Exchange Commission on February 26, 2024. The Company issued the following statement: "R1 welcomes open, constructive communications with all stockholders and encourages input that advances our shared goal of enhancing stockholder value. Consistent with its fiduciary duties, and in consultation with its independent advisors, the Special Committee will carefully review the communications from New Mountain Capital and evaluate strategic alternatives to determine the course of action that it believes is in the best interests of R1 and its stockholders. R1 remains focused on providing clients with world-class revenue cycle solutions to help providers improve their financial performance and deliver an exceptional patient experience. No assurances can be given regarding the outcome or timing of the Special Committee's review process. R1 does not intend to make any further public comment regarding the review unless and until it has approved a course of action for which further disclosure is appropriate."

08:18 EDT Children's Place receives $48.5M second tranche of financing - The Children's Place has received from its majority shareholder, Mithaq Capital SPC, the second tranche of interest-free, unsecured and subordinated term loan funding contemplated by the previously announced Unsecured Promissory Note, dated February 29, 2024, entered into between Mithaq and the Company, in the amount of $48.6 million. As previously announced, Mithaq provided the initial tranche of $30 million to the Company pursuant to such Unsecured Promissory Note on February 29, 2024, also in the form of an interest-free, unsecured and subordinated term loan. On March 8, 2024, with the funding of the Second Mithaq Term Loan, the resignations from the Board of Norman Matthews, John E. Bachman, John A. Frascotti, Debby Reiner and Michael Shaffer have become effective and the size of the Board has been reduced to six. Jane Elfers will continue to serve in her role as President, CEO and director of the Company. In addition, the new Board has appointed Douglas Edwards - who served in a number of different roles with Wells Fargo & Company before his retirement in 2022, including Executive Vice President and Interim General Counsel - to serve on the reconstituted Board as an independent director, with immediate effect upon the completion of customary lender due diligence required by the previously announced forbearance agreement entered into by the Company and the other lenders party thereto. The Company continues to expect to be in a position to close the previously announced $130 million term loan in March 2024, as contemplated by the non-binding term sheet that the Company entered into with 1903P Loan Agent, LLC. The Company is also pursuing improved terms with Gordon Brothers as well as alternative financing on terms no less favorable in the aggregate to the Company.

08:15 EDT Arcosa to acquire Ameron from NOV Inc. for $180M in cash - Arcosa (ACA) announced that it has entered into a definitive agreement to acquire Ameron Pole Products or Ameron, from NOV (NOV) for $180M in cash. Founded in 1970, Ameron is a leading manufacturer of highly engineered, premium concrete and steel poles for a broad range of infrastructure applications, including lighting, traffic, electric distribution, and small-cell telecom. For the year ended December 31, Ameron had revenues of approximately $94M Mand Adjusted EBITDA of approximately $20M, implying a 9.0x EBITDA acquisition multiple. Commenting on the transaction, Antonio Carrillo, Arcosa's President and Chief Executive Officer, noted, "As we continue to effectively deploy capital into Arcosa's growth businesses, we believe Ameron is an excellent strategic fit. It provides entry into the complementary steel and concrete lighting pole market while expanding our product offerings in traffic and telecom. ..The Company expects to fund the $180M purchase price with a combination of cash on-hand and borrowings available under its revolving credit facility. The transaction, which has been approved by the Company's Board of Directors, is subject to customary closing conditions and regulatory provisions under the Hart-Scott-Rodino Act and is expected to close in the second quarter of 2024.

08:14 EDT Immuneering doses first patient in Phase 2a trial of IMM-1-104 - Immuneering Corporation announced that the first patient has been dosed in the Phase 2a portion of its Phase 1/2a clinical trial of IMM-1-104, its lead program. IMM-1-104 is designed to provide universal-RAS activity through deep cyclic inhibition of MEK in the MAPK pathway with once-daily oral dosing. The Phase 2a portion of the Phase 1/2a clinical trial of IMM-1-104 is expected to include approximately 150 patients in five arms at our recommended Phase 2 dose of 320 mg once daily. The five arms are as follows: IMM-1-104 monotherapy in patients with pancreatic ductal adenocarcinoma in the first- or second-line setting. IMM-1-104 monotherapy in patients with RAS-mutant melanoma in the second- or third-line setting post-immunotherapy, or in the first-line setting for patients who are not candidates for existing therapies. IMM-1-104 monotherapy in patients with RAS-mutant non-small cell lung cancer in the second- or third-line setting. IMM-1-104 in combination with mFOLFIRINOX in patients with PDAC in the first-line setting. IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel in patients with PDAC in the first-line setting.

08:12 EDT A-Mark Precious Metals' JM Bullion acquires Gold.com website domain - JM Bullion, a wholly-owned subsidiary of A-Mark Precious Metals, has acquired the gold.com domain. With this acquisition, JMB now owns both gold.com and silver.com, two of the most recognizable domains in the precious metals industry.

08:11 EDT Arcutis Biotherapeutics appoints Todd Tucker as CHRO - Arcutis Biotherapeutics announced the promotion of Todd Tucker to senior vice president and Chief Human Resources Officer, effective immediately. Mr. Tucker joined Arcutis in July 2020 as executive director and head of human resources and was promoted to vice president of human resources in March 2022.

08:11 EDT SaverOne 2014 expands collaboration with GB Tours - SaverOne 2014 has expanded its collaboration and signed a further agreement with GB Tours to install the SaverOne System on the full fleet of GB Tours' fleet of public transportation and tour buses. GB Tours is a leading Israel-based public transportation company that operates public transportation lines as well as tour buses with a fleet of about one hundred buses. This order follows the conclusion of a successful pilot of the SaverOne System on twenty of GB Tours' buses. Over the coming weeks, SaverOne will install its system across the full fleet of GB Tours' buses, amounting to a further 77 public transportation and tour buses.

08:09 EDT Getaround announcespromotion of AJ Lee as COO - Getaround (GETR) announced the promotion of AJ Lee, Getaround's former General Manager of Gig, to Chief Operating Officer. In this role, Lee will report to Getaround CEO Eduardo Iniguez, to accelerate the Company's growth and path to profitability. Lee will have broad responsibilities including operations, marketing, sales, and other functions to drive operational excellence across the Company. Previously, he served in senior roles in strategy, operations, and marketing at technology companies including NEXT Trucking and Amazon (AMZN). "It's an honor to be appointed as Getaround's COO where my focus will be on establishing strong financial discipline and driving operational efficiencies, allowing us to invest in our future growth," said Lee. "I look forward to rolling up my sleeves alongside such a talented and dedicated team, and I'm confident that together, we can move fast, execute effectively, and deliver value for our car owners, renters and investors."

08:08 EDT Tonix Pharmaceuticals presents additional efficacy data from RESILIENT - Tonix Pharmaceuticals announced the presentation of additional efficacy data from RESILIENT, the second positive Phase 3 study evaluating Tonmya for the management of fibromyalgia, at the 6th International Congress on Controversies in Fibromyalgia in Brussels, Belgium, March 7-8, 2024. In presenting more detailed data from the RESILIENT study, Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, said, "We previously reported statistically significant and clinically meaningful results in all six key secondary endpoints related to improving sleep quality, reducing fatigue, and improving overall fibromyalgia symptoms and function. We now report that the effect sizes of the five continuous key secondary outcomes measures ranged from 0.3 to 0.5. The results also showed that Tonmya treatment resulted in an improvement in cognitive dysfunction, or 'brain fog', measured by the change in the Fibromyalgia Impact Questionnaire-Revised memory item. The FIQ-R cognitive item showed nominal improvement in Tonmya-treated patients vs placebo-treated patients with a p=0.001 and effect size of 0.31. Together, we believe the activity of Tonmya on pain, sleep quality, fatigue and brain fog are indicative of broad-spectrum activity of Tonmya and suggest that Tonmya treats fibromyalgia at a syndromal level." As previously announced, RESILIENT met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo in participants with fibromyalgia. RELIEF, the first Phase 3 trial of Tonmya 5.6 mg in fibromyalgia, was completed in December 2020. It also met its pre-specified primary endpoint of daily pain reduction compared to placebo. Tonix plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2024 and has scheduled a pre-NDA meeting with FDA in the second quarter of 2024. Tonmya was not associated with increases in systolic or diastolic blood pressure or body weight, nor were there any reported sexual side effects in the RESILIENT trial. In addition, when systematically investigated using the Changes in Sexual Functioning Questionnaire short form women who received study drug had a higher CSFQ-14 total score relative to those who received placebo, which is consistent with improved sexual function.

08:07 EDT Arcosa to acquire Ameron from NOV Inc. for 180M in cash - Arcosa (ACA) announced that it has entered into a definitive agreement to acquire Ameron Pole Products or Ameron, from NOV (NOV) for $180M in cash. Founded in 1970, Ameron is a leading manufacturer of highly engineered, premium concrete and steel poles for a broad range of infrastructure applications, including lighting, traffic, electric distribution, and small-cell telecom. For the year ended December 31 , Ameron had revenues of approximately $94 Mand Adjusted EBITDA of approximately $20M, implying a 9.0x EBITDA acquisition multiple. Commenting on the transaction, Antonio Carrillo, Arcosa's President and Chief Executive Officer, noted, "As we continue to effectively deploy capital into Arcosa's growth businesses, we believe Ameron is an excellent strategic fit. It provides entry into the complementary steel and concrete lighting pole market while expanding our product offerings in traffic and telecom. ..The Company expects to fund the $180M purchase price with a combination of cash on-hand and borrowings available under its revolving credit facility. The transaction, which has been approved by the Company's Board of Directors, is subject to customary closing conditions and regulatory provisions under the Hart-Scott-Rodino Act and is expected to close in the second quarter of 2024.

08:06 EDT ClearPoint Neuro announces publication on Prism Neuro Laser Therapy System - ClearPoint Neuro announced that preclinical results of an in vivo validation study have been published in the Journal of Neurosurgery. These data demonstrate that the ClearPoint Prism Neuro Laser Therapy System provides accurate, near real-time temperature of the brain tissue with a mean absolute error of less than1 degrees C. Additionally, the morphology of the lesion, as visualized by Thermoguide MR-thermometry software, correlated well with histopathology. The research was conducted by the Company and its Swedish partner, Clinical Laserthermia Systems AB, with Dr. John Rolston leading the study as Principal Investigator. The aim of the study was to evaluate the safety, accuracy, and efficacy of the Prism System. This was achieved by 1) demonstrating a predicted safety margin via survival histology; 2) determining the Thermal Damage Thresholds that best predict irreversible tissue damage based on said histology; and 3) evaluating the accuracy of temperature prediction compared to actual temperature changes in vivo. The Prism System features the only non-cooled neurosurgical laser applicators on the market. ClearPoint's next-generation laser applicator technology eliminates the need for external cooling, simplifying setup, reducing power and ablation time, lessening imaging artifact, and enabling more efficient workflows. Currently, Prism is in limited market release at select academic medical centers across the United States.

08:04 EDT Wipro expands partnership with Nutanix to launch new business unit - Wipro (WIT) and Nutanix (NTNX) announced the launch of a new Nutanix-focused business unit. The new business unit will combine the expertise of Wipro FullStride Cloud with Nutanix Cloud Platform to enhance joint solution engineering and expand go-to-market strategies. The engagement aims to enhance agility, speed, and innovation for enterprises and help them build more powerful, resilient, and agile cloud operating models.

08:03 EDT SeaChange to be acquired by Partner One for $30M - SeaChange International has entered into an asset purchase agreement under which an affiliate of Partner One will acquire substantially all of SeaChange's assets related to its product and services business and will assume certain liabilities, for a purchase price of $30 million, less SeaChange's cash and cash equivalents at closing. SeaChange has traditionally supported clients' Operator TV systems, Advanced Advertising insertion platforms, the StreamVid streaming enablement solution, and the Xstream FAST channel service platform. The Company currently expects the transaction will result in net proceeds to SeaChange of between $13-15 million upon Closing. The Asset Sale, which has been approved by SeaChange's Board of Directors, is subject to various terms and closing conditions, including approval by a majority of the shares of SeaChange's outstanding common stock. Subject to such closing conditions, the Closing is expected to occur in the first quarter of SeaChange's fiscal year 2025. Following the Closing, the Company will retain its cash and cash equivalents, and U.S. and state net operating loss carryforwards which may be available to offset future tax income. The Purchase Agreement provides that, during the period beginning on the execution date of the Purchase Agreement and continuing until 11:59 p.m., New York City time, on April 8th, 2024, SeaChange and its subsidiaries have the right to, directly or indirectly: encourage, solicit, initiate, facilitate or continue inquiries regarding an offer or proposal that constitutes, or could reasonably be expected to lead to, an acquisition proposal and enter into discussions or negotiations with any person concerning a possible acquisition proposal; provided however, SeaChange and its subsidiaries will not disclose any non-public information about Partner One or the Asset Sale and related transactions, without prior written approval of Partner One. There can be no assurances that the solicitation of such possible acquisition proposals will result in a Superior Proposal It is not anticipated that any developments will be disclosed with regard to this process unless the Board makes an affirmative decision to proceed with a Superior Proposal. In addition, SeaChange may, subject to the terms of the Purchase Agreement, respond to unsolicited, bona fide, written alternative acquisition proposals. The Purchase Agreement also contains a $1 million termination fee payable to Partner One in connection with the termination of the Purchase Agreement under certain circumstances, such as consummation of an alternative acquisition transaction in connection with a Superior Proposal. In addition, concurrently with the execution of the Purchase Agreement, a significant stockholder of the Company, that cumulatively owns 30.5% of the shares of SeaChange's outstanding common stock, has entered into a voting agreement with Partner One pursuant to which the Significant Stockholder has agreed, subject to the terms and conditions therein, to vote its shares of common stock of the Company to approve the Asset Sale at the SeaChange special meeting of stockholders.

08:01 EDT Mind Technology reports order for ultra-high resolution survey system - MIND Technology announced that its Seamap unit has been awarded an order by ATLAS MARIDAN ApS, a company of the ATLAS ELEKTRONIK Group, to provide a specialized SeaLink 2-D & 3-D, ultra ultra-high resolution seismic streamer system. It is anticipated the system will be utilized in ultra-high resolution seismic site surveys in accordance with ISO19901 protocols. Mark Welker, Vice President of MIND and Seamap Managing Director, stated, "We are excited to have received this initial order from ATLAS ELEKTRONIK, and we look forward to demonstrating the elite capabilities of our SeaLink technology and cultivating this new customer relationship, which we believe will result in additional orders in the future. The UUHR SeaLink systems can, we believe, be of great benefit in de-risking offshore windfarm installation by detecting sub-seafloor boulders and other geohazards. We think this further establishes Seamap as a key supplier of equipment for renewable energy projects."

07:56 EDT Sound Group upgrades AI-powered app, incorporates voice tech - Sound Group has upgraded one of its AI-powered applications and launched a new version, incorporating voice technology and the latest AI models. Constantly engaged in in-depth research and exploration of cutting-edge technologies such as AIGC, Sound Group is committed to advancing technological productization, deeply integrating AI and the Company's proprietary technologies, as well as expanding the scope where these technologies can be applied. Leveraging the advantages of voice-based technology, Sound Group further optimized its AI products and implemented voice input functionality in the new version of its AI application. This was achieved by employing Natural Language Processing, Automatic Speech Recognition, Large Language Models and other related technologies, as well as integrating the GPT-4 model by OpenAI. These efforts are aimed at enhancing product usability and improving the user experience.

07:53 EDT IntelGenx enters amended, restated loan agreement with atai Life Sciences - IntelGenx Technologies has entered into a third amended and restated loan agreement dated as of March 8, 2024 with atai Life Sciences, pursuant to which, among other things, atai has agreed to make one additional term loan in the amount of US$1,000,000 to IntelGenx Corp., which loan is to be disbursed within three business days of the execution of the Loan Agreement, and one additional term loan in the amount of US$1,000,000 to IntelGenx Corp., which loan is to be disbursed upon the achievement of a pre-defined milestone. The Additional Term Loans will mature on February 1, 2026. Subject to obtaining approval from the Toronto Stock Exchange, the Loan Agreement provides for the ability for atai to convert, from time to time, the principal outstanding under the First Tranche Loan into shares of common stock of the Company at a conversion price of US$0.185 per Share, and the principal outstanding under the Second Tranche Loan into Shares at a conversion price equal to the greater of the Conversion Price and the 5-day volume-weighted average price of the Shares on the TSX ending on the day preceding the disbursement by atai of the Second Tranche Loan to the Company or IntelGenx, less the maximum permissible discount under the applicable TSX rules. Additionally, and subject to approval of the TSX, the Company may elect, with the consent of atai, to pay any accrued but unpaid interest on the Additional Term Loans in Shares at a price per Share equal to the 5-day VWAP of the Shares ending on the day that is the second business day before the day the interest becomes due and payable, less the maximum permissible discount under the applicable TSX rules. Concurrently to entering into the Loan Agreement, the Company has issued 4,000,000 warrants to atai. The Warrants entitle atai to purchase Shares at a price of US$0.17 per Share, for a period of 36 months following their issuance. Furthermore, on December 5, 2023, atai made a loan in the amount of US$500,000 to the Company, which will mature on December 31, 2024.

07:50 EDT Acreage Holdings launches adult-use sales at Vernon, CT dispensary - Acreage Holdings announced the commencement of adult-use sales at its Vernon, Connecticut dispensary. The Botanist Vernon is now operating as a hybrid dispensary, providing its full suite of products to both medical patients and adult-use customers.

07:49 EDT Applied UV's SteriLumen files patent application with USPTO - Applied UV announced that its SteriLumen subsidiary has filed a new patent application with the United States Patent and Trademark Office entitled "Disinfection System Comprised of Multiple Wavelengths Each Controlled Optimally" with claims pertaining to a method of integrating disinfection systems uniquely designed to optimize environmental cleanliness across different rates of occupancy within healthcare settings, especially operating rooms. Management estimates the annual market size to be in excess of $150M per year with roughly 4,000 operating rooms renovated annually in the United States.

07:47 EDT Aecon Group appoints Jerome Julier a CFO - Aecon Group announced that Jerome Julier has been appointed to the position of Executive Vice President and Chief Financial Officer, effective April 8, 2024. Most recently served as Managing Director and Co-Head of CIBC Capital Markets' Global Diversified Industries investment banking practice.

07:45 EDT Lexeo Therapeutics expects cash to fund operations into 2027 - As of December 31, 2023, cash and cash equivalents were $121.5 million, excluding the $95.0 million gross proceeds expected to be raised in the private placement announced today. Lexeo expects the additional funds raised in the financing to extend its runway into 2027.

07:40 EDT Microbix Biosystems unveils test controls for head, neck cancer - Microbix Biosystems is presenting results of Quality Assessment Products for supporting the quality control of histology and PCR-based tests driven by tissue-samples of Head and Neck cancer caused by human papilloma virus. Its results presentation will be made at EUROGIN 2024, an international collaborative conference and exhibition focused upon innovations in HPV research and global cancer solutions taking place in Stockholm, Sweden from March 13 to 16, 2024. While HPV is best known for causing cancers of the cervix in women, this virus family also causes cancer in other bodily tissues. Such further types of HPV-driven cancer include those of the "Head and Neck," collectively tumours inside and behind the nose, throughout the mouth (including the tongue, gums, and palate), all sections of the throat, and the voice box. Diagnosis of such cancers is made from tissue sample analyses that look for the presence of cancerous cells via histology and the presence of viral DNA by PCR. Unfortunately, a lack of standardized and reproducible reference samples makes it challenging to control the recommended test workflows for diagnosing such cancers. Microbix and collaborators at Sunnybrook Health Sciences Centre and Dartmouth-Hitchcock Medical Center worked to address this need. Microbix developed homogenous and reproducible simulated-specimen paraffin blocks to monitor the accuracy and reliability of such testing, being presented via a poster titled "Evaluating Diagnostic Workflows for Oropharyngeal Squamous Cell Carcinoma Detection Using Simulated Specimens Mounted on Slides." The authors of the poster conclude that this QAP is innovative and clinically-relevant on multiple levels, namely that (i) these are the first simulated and standardized slides for use as prospective whole workflow QC materials for Head and Neck cancer reflex histology with follow up PCR-based confirmatory testing, and these prototype HPV-positive and HPV-negative contrived-specimen slides are homogeneous and reproducible QC materials that can be used to standardize inter-laboratory methodologies, monitor accuracy, and support new proficiency-testing and accreditation schemes for laboratories conducting histologic and PCR test driven detection of such cancers. Microbix will now work to optimize its tissue scaffold designs for supporting both histology and PCR workflows. These standardized and reproducible tissue-oriented test controls will then be added to Microbix's catalogue of QAPs, expanding its activities into support of oncology workflows alongside its wide range of infectious disease test controls. The global market for diagnostic tests for cancer is currently estimated at US$ 18-20 billion, with a projected compound annual growth rate of over 10%.

07:38 EDT Lifeist Wellness CEO Meni Morim to step down - Chairman Branden Spikes said, "As Lifeist prepares for a truly transformative year, we have received meaningful feedback from shareholders regarding the strategic focus of Lifeist going forward, its compensation structure and incentivization of management, and the value that fresh insights and approaches might bring to Lifeist's core businesses. At this time, Meni Morim wishes to announce his intent to step down as CEO of Lifeist after the Board of Directors, led by Mr. Branden Spikes, has completed its executive search and appointed a new CEO to assume leadership of Lifeist. Until a new CEO has been selected, Mr. Morim has agreed to remain and will continue to serve as CEO, at reduced compensation, to keep the operating subsidiaries on track through the strategic pivot to increase focus on Mikra Cellular Sciences and Aussie Vapes. Furthermore, the members of the Board of Directors have also individually agreed to reduce their own compensation in order to cut costs and improve cash flow for Lifeist in this pivotal year. We are more confident than ever in Lifeist's roadmap to cash flow positivity and profitability. Initiatives presently underway at its operating subsidiaries hold great promise for the realization of shareholder value, and we look forward very much to reaching new milestones in 2024."

07:35 EDT Psyence Group provides update following spin out of therapeutic unit - Further to the announcement by Psyence Group of the closing of the business combination of its subsidiary, Psyence Biomedical with Newcourt Acquisition Corp, a special purpose acquisition company, and the subsequent listing of PBM on the NASDAQ stock exchange with the trading symbol "PBM", Psyence Group provides a corporate update. Psyence Biomed II, the therapeutics division of Psyence Group and target business of the Business Combination, is now a wholly-owned subsidiary of NASDAQ traded PBM. Psyence Biomed consists of the clinical trial business and the development of natural psilocybin products in the context of palliative care. It has partnered with iNGEN Pty Ltd to conduct Psyence Biomed's clinical trial in palliative care. iNGEN is an Australian based, globally focused contract research organisation with extensive experience working in the psychedelic pharmaceutical drug development and clinical research industry. Upon the close of the Business Combination effective January 25, 2024, Psyence Group was issued 5,000,000 common shares in PBM, equal to approximately a 37% interest in PBM. The common shares of PBM held by Psyence Group are subject to a trading lock-up period ending on the earliest of one hundred eighty days after the Closing and a change of control event. The Company is taking tax and corporate securities advice on the possibility of distributing the PBM shares to Psyence Group shareholders. As a result of the Spin-Out, Psyence Group has significantly reduced its operating costs by no longer having to fund the clinical trial being carried out by iNGEN, and by substantially reducing its general and administrative costs, as well as removing the compensation of a number of senior executives and consultants who will now be employed by PBM. Dr Neil Maresky has assumed the role of CEO of PBM to oversee the Psyence Biomed business and has resigned as CEO of Psyence Group. Dr Clive Ward-Able has been appointed as Medical Director for PBM to support the CEO in the execution of the Psyence Biomed clinical trial and has resigned as Medical Director of Psyence Group. Warwick-Corden Lloyd will step down as the Chief Financial Officer of Psyence Group to assume the position of Chief Financial Officer of PBM. Adri Botha, Psyence Group's Group Financial Manager, will act as Interim Chief Financial Officer of Psyence Group while the search for a new Chief Financial Officer and Chief Executive Officer continues. Since these executives are moving over to PBM, no termination payments are being paid by the Company, and unvested equity incentives and compensation securities will be cancelled. In addition hereto, a senior consultant's contract has also been terminated as the services related largely to the Psyence Biomed business. As a sign of confidence in the business, such senior consultant has agreed to settle a portion of his outstanding consulting fees totalling C$60,550 in common shares in the Company and will receive 1,668,044 common shares at a price of C$0.03630 per share, subject to approval from the Canadian Securities Exchange. Christopher Bull and Dr Neil Maresky have resigned as members of the Psyence Group board to join the board of PBM. Jody Aufrichtig and Alan Friedman will retain their respective board positions with Psyence Group with Jody as continuing executive chairman of the board. The Company is also pleased to announce the strategic restructuring of its non-clinical business through a conditional M&A transaction. The conditional transaction involves the transfer of the Company's non-clinical subsidiaries Mind Health the vehicle housing the psilocybin cultivation, extraction, and production operations in Southern Africa, and Psyence UK Group, the entity engaged in Active Pharmaceutical Ingredient (and IP development, and the functional mushroom brand GOODMIND to a third-party private company which will be responsible for raising the private investment required and ongoing finance to continue the operations of the Non-Clinical Assets. PriveCo will concentrate on growing, production and extraction operations, and creating an API for commercialization in the legal research and development and medical markets globally. Psyence Group will retain sales and distribution rights for all products and services developed and offered by PriveCo with the intention of creating a marketplace therefor in the psychedelics industry. As consideration for the Conditional Transaction, the Company will receive C$1 million in shares of PriveCo priced at PriveCo's most recent financing at the time of close. The Company will also be entitled to a 3.5% royalty on net sales generated through the non-clinical assets with respect to the intellectual property transferred as part of the Conditional Transaction for a period of 7.5 years.

07:31 EDT Actinium Pharmaceuticals launches Actinium-225 focused strategic initative - Actinium Pharmaceuticals announced that it has launched a strategic initiative focused on the manufacture of the medical isotope Actinium-225 leveraging its propriety cyclotron-based method. Actinium's intellectual property portfolio relating to its cyclotron-based production method includes 5 issued U.S. patents and 49 issued international patents as well as significant technical know-how. Ac-225 produced using Actinium's method is highly pure and identical to the current gold-standard manufacturing method using a Thorium-229 generator but has the potential to be lower-cost at commercial scale and is a higher yielding approach. Specifically, Actinium's Ac-225 based technology and production methods are grounded in several U.S. and International patents that cover the following areas: End-to-end solution including processing and recycling of Radium-226 starting material; Production of up to 100 mCi of Ac-225 per production cycle; Utilizes a medium energy cyclotron; Expected cost 10 - 20 times lower than currently available material. Currently, the majority of Ac-225 is supplied by the United States Department of Energy who derives Ac-225 from the natural decay of thorium-229 from so-called "thorium-cows". Actinium Pharmaceuticals, Inc. has maintained supply agreements with the DOE since 2009. The DOE has stated that it is exploring the generation of new thorium cows and production via a cyclotron. In addition, multiple government and non-governmental entities globally are focused on Ac-225 production using various methods and have represented that clinical grade Ac-225 could be available over the next several years. However, at this time, the majority of material available is research grade and there is limited availability of clinical grade Ac-225 outside of the material supplied by the DOE. The relative scarcity of Ac-225 has led to rapidly escalating procurement costs in recent years.

07:29 EDT Amplify Energy provides update on Southern California oil sheen - Amplify Energy continues to monitor the status of the oil sheen reported on March 7, 2024, off the coast of Huntington Beach, California. Amplify has the following updates to report: Amplify remains confident that the sheen is not related to our operations. While Amplify reported a minor discharge of produced water from Platform Elly that occurred on the morning of March 8th, U.S. Coast Guard/Unified Command reported over the weekend that, "the characteristics of the produced water from Platform Elly do not align with what was observed from the sheen. Currently, we do not believe the sheen and the discharge are related." The Coast Guard also noted that offshore recovery assets would be demobilized following a March 10th overflight that "did not observe any sheen offshore." Amplify's Beta field operations and development program have not been disrupted. We continue to cooperate with the Unified Command, U.S. Coast Guard and other relevant authorities and provide support in any way we can.

07:26 EDT mdf Commerce to be acquired by KKR for C$5.80 per share - mdf commerce (MECVF) announced it has entered into an arrangement agreement to be acquired by funds managed by KKR (KKR) in an all-cash transaction. Upon completion of the Transaction, mdf commerce will become a privately held company. The Company's platforms and services empower businesses around the world, supporting them in generating billions of dollars in transactions on an annual basis. mdf commerce's North American eProcurement platform serves over 6,500 government agencies and more than 650,000 suppliers across Canada and the United States and provides a strong foundation to build a leading government software platform. Following the closing of the Transaction, KKR will support mdf commerce in creating an equity ownership program to provide all employees the opportunity to participate in the benefits of ownership of the Company. This strategy is based on the belief that employee engagement is a key driver in building stronger companies. Since 2011, KKR portfolio companies have awarded billions of dollars of total equity value to over 60,000 non-management employees across more than 40 companies. KKR is making its investment in mdf commerce through its Ascendant Strategy, which invests in middle market businesses in North America as part of KKR's Americas Private Equity platform. Consideration of C$5.80 per issued and outstanding common share of the Company, payable entirely in cash, represents a premium of approximately 58% to the closing price of the Common Shares on the Toronto Stock Exchange on March 8, 2024 of C$3.68 per Common Share, a premium of approximately 59% to the 20-day volume-weighted average share price on the TSX for the period ending on March 8, 2024 of C$3.65 per Common Share, and a 30% premium to the 52-week high price on the TSX of C$4.45 per Common Share achieved on December 8, 2023; Certainty of value and immediate liquidity: The shareholders of mdf commerce will receive a price of C$5.80 per Common Share, payable entirely in cash, which provides certainty of value and immediate liquidity; Unanimous mdf commerce Board recommendation: The Board unanimously recommends that Shareholders vote in favour of the Transaction; Alignment with major shareholders: KKR is closely aligned with mdf commerce's management in a shared vision for the future of the Company and will leverage the expertise of the existing management team led by Luc Filiatreault, President and Chief Executive Officer, to continue to support mdf commerce's growth strategy and to build a global leader headquartered in Quebec. The Transaction is the result of an extensive formal sale process conducted by the Board, pursuant to which several proposals from interested parties were considered. The Board has evaluated the Arrangement Agreement with the Company's management and legal and financial advisors and has unanimously determined that the Transaction is in the best interests of the Company and is fair to the Shareholders. The Board also unanimously recommends that the Shareholders vote in favour of the Transaction at the special meeting of Shareholders to be called to approve the Transaction. The Transaction is expected to close in the second quarter of calendar 2024, subject to the receipt of the required approvals from the Company's shareholders and certain regulatory approvals, as well as the satisfaction of other customary closing conditions. The Supporting Shareholders, who currently collectively own approximately 12.4% of the outstanding Common Shares, have entered into support and voting agreements pursuant to which they have agreed to vote their Common Shares in favour of the Transaction, subject to certain conditions.

07:22 EDT FibroGen appoints Deyaa Adib as CMO - FibroGen announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities. The appointment is effective March 11, 2024. Prior to joining FibroGen, he was the Chief Medical Officer of Triumvira Immunologics

07:21 EDT Ventyx Biosciences expects cash to fund operations into 2H26 - We reported cash, cash equivalents and marketable securities of $252.2 million as of December 31, 2023. Combined with gross proceeds of approximately $100 million from our recent PIPE financing, and based on our revised pipeline priorities, we now expect our current cash, cash equivalents and marketable securities to fund planned operations into at least the second half of 2026.

07:19 EDT ADMA Biologics announces FDA approval of sBLAs for ASCENIV, BIVIGAM - ADMA Biologics announced the United States Food and Drug Administration's approval for its supplemental Biologics License Applications for both ASCENIV and BIVIGAM to extend the approved 4-week room temperature storage conditions during the first 24 months of shelf life, to allow for a 4-week room temperature storage at any time during the entire 36-month approved shelf life. The room temperature approval applies to all existing ASCENIV and BIVIGAM lots currently in the commercial supply chain as well as to future production of ASCENIV and BIVIGAM. The newly approved extension of room temperature storage conditions for both ASCENIV and BIVIGAM is immediately effective, and both products are commercially available to U.S. healthcare providers and patients.

07:15 EDT Pluri receives patent approval for 3D bioreactor technology - Pluri announced an important expansion to its intellectual property portfolio with a new patent approval, that is designed to reshape the agricultural technology landscape. The patent titled "A System for 3D Cultivation of Plant Cells and Methods of Use" represents a major breakthrough in Pluri's proprietary 3D bioreactor technology, enabling efficient cultivation of plant cells across various applications, from sustainable agriculture to critical healthcare solutions. An immediate application for the patent is PluriAgtech's sustainable cell-based coffee. The 3D cell expansion technology can produce high-quality coffee with 98% less water and 95% less growing area. Pluri's patent and 3D cell expansion technology can also potentially address an emerging gap in agricultural healthcare, as approximately one-fifth of the 50,000 medical plants used today are on a list of threatened species.

07:14 EDT Choice Hotels ends attempt to buy Wyndham, ups share buyback - Choice Hotels (CHH) this morning ended its attempt to acquire Wyndham Hotels & Resorts (WH) and increased its stock buyback plan. "While the support from Wyndham stockholders tendering into the exchange offer was significant considering the number of investors structurally prevented from participating at this stage, it was not sufficient for Choice to conclude - particularly when taking into account the Wyndham board's obvious continuing disinterest in a combination - that a path towards a transaction is available at this time," the company said in a statement. Choice also announced that its board approved an increase in the number of shares authorized under its share repurchase program by 5M shares. Choice shares are up 3% to $124.21 in premarket trading while Wyndham shares are down 4% to $72.75.

07:13 EDT Perion Network enters DSP partnership in China with Way.io - Perion Network announced its first domestic demand side platform, or DSP, partnership in China with Way.io through its programmatic digital out of home, or DOOH, platform, Hivestack. Hivestack's platform is already integrated with 16 DOOH media owners in China, covering an network of over 1M screens across more than 93k sites and generating access to 203B impressions amongst a variety of audiences and popular advertising seasons.

07:11 EDT Lexicon preparing to resubmit sotagliflozin NDA mid-year - Lexicon Pharmaceuticals announced that, following the receipt of recent feedback from FDA, it is preparing to resubmit its New Drug Application for sotagliflozin as an adjunct to insulin therapy for glycemic control in patients with type 1 diabetes and chronic kidney disease. The resubmission is planned for mid-year, with an anticipated six-month regulatory review period. FDA issued a complete response letter regarding the NDA for sotagliflozin for type 1 diabetes in 2019 and, at Lexicon's request, issued a public Notice of Opportunity for Hearing in 2021 on whether there were grounds for denying such approval. Lexicon and FDA subsequently agreed in late 2023 to hold the NOOH proceedings in abeyance in order to engage in discussions regarding a path forward for resubmission and potential approval of the NDA.

07:10 EDT Wyndham falls 4% to $72.75 after Choice Hotels ends takeover attempt

07:09 EDT Apellis appoints Philip Ferrone as chief medical retina advisor - Apellis Pharmaceuticals announced that retina specialist Philip Ferrone, M.D., will join the company as Chief Medical Retina Advisor, effective March 18. Ferrone will continue to serve as the director of clinical research at Vitreoretinal Consultants in New York. He is a past president of the ASRS and has been on its board of directors for 18 years.

07:07 EDT L.S. Starrett Co to become private in $16.19 per share pact with MiddleGround - L.S. Starrett announced that it has entered into a definitive merger agreement in a go-private transaction with an affiliate of MiddleGround Capital in an all-cash transaction for $16.19 per share. The purchase price represents an approximately 63% premium to the closing stock price of the company's stock on March 8, the last trading day prior to announcing the transaction. The proposed transaction has been approved by the Starrett board of directors. MiddleGround intends to fund the transaction with a combination of cash from MiddleGround Partners III, L.P. and committed financing, which is not subject to any contingency. The transaction is expected to close in mid-2024, subject to the requisite approval by Starrett's shareholders and other conditions to closing. Following completion of the transaction, Starrett will become a wholly owned subsidiary of MiddleGround and Starrett's Class A common stock will no longer be listed on any public market.

07:07 EDT Crane NXT to acquire OpSec Security for $270M in cash - Crane NXT announced it has signed a definitive agreement with Investcorp Technology Partners Investcorp to acquire OpSec Security OpSec for $270M in cash, subject to customary adjustments. OpSec is a global leader in brand protection and authentication solutions, serving the world's most recognized brands, as well as government agencies and financial institutions. Aaron W. Saak, Crane NXT's President and Chief Executive Officer stated: "OpSec is an excellent fit with our portfolio of technologies that secure, detect, and authenticate our customers' most valuable assets. The authentication and brand protection markets are large and growing, bolstered by secular mega trends, including the continuous rise of counterfeiting and proliferation of online marketplaces, as well as digital media and piracy...The acquisition will expand Crane NXT's capabilities across the entire product and brand authentication value chain. ..This agreement does not include the acquisition of Zacco, currently part of OpSec, which will remain with Investcorp. The parties intend for OpSec and Zacco to continue a business relationship post-acquisition. Excluding Zacco, OpSec expects to generate approximately $130 M in revenue for fiscal 2024. Crane NXT expects the acquisition to be accretive to Adjusted EPS in 2025 and to achieve double digit ROIC by year five, driven by the growth outlook for OpSec and transaction synergies. The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions.

07:04 EDT DISQO connects to Inscape's ACR TV viewing data - DISQO is now connected to Inscape's automatic content recognition TV viewing data, strengthening DISQO's Brand Lift and Outcomes Lift products that let advertisers measure the cross-media and full-funnel impact of ad campaigns. With DISQO, clients can connect brand metrics like awareness, favorability, and purchase intent to performance outcomes like search, site visits, and shopping - across their whole multimedia campaign.

07:03 EDT Integra Resources closes acquisition of strategic claims at DeLamar project - Integra Resources announced that further to its news release dated February 28, 2024, the company, through its wholly owned subsidiary, DeLamar Mining Company, has completed the acquisition of seventeen patented claims in the Rich Gulch area. The Rich Gulch claims are located adjacent to the Florida Mountain Deposit at the DeLamar project in Owyhee County, State of Idaho. Under the terms of the option agreement dated November 1, 2023 as between DMC and an arm's length vendor, DMC has the Option to purchase all of the member interests of Rich Gulch, LLC, pursuant to a membership interest purchase agreement, to be entered into as between DMC and the Vendor. Rich Gulch, LLC is the sole owner of the seventeen patented Rich Gulch claims. On February 28, 2024, DMC exercised the Option and on March 8, 2024, the parties entered into the MIPA. Under the terms of the MIPA, DMC acquired all of the Interests in exchange for $2,100,000. The Purchase Price was satisfied through the issuance of 2,959,769 common shares in the capital of the company. The Shares are subject to a statutory hold period of four months and a day expiring on July 9, 2024, and a voluntary lock-up from which 25% will be released 45 and 90 days, respectively, from closing, and 50% to be released on January 3, 2025. As consideration for the grant of the Option pursuant to the Option Agreement, DMC completed a $24,000 cash payment to the Vendor.

07:01 EDT Mallinckrodt publishes findings from review of Acthar Gel outcomes - Mallinckrodt announced the publication of findings from a retrospective chart review of Acthar Gel treatment outcomes for African American and non-African American patients with symptomatic sarcoidosis - including treatment patterns, co-medication use, and overall health outcomes. This analysis suggested that Acthar Gel treatment was associated with similar improvements in health outcomes, a reduction in symptoms, and reduced co-medication use in both African Americans and non-African Americans with symptomatic sarcoidosis. The manuscript was recently published online in Therapeutics & Clinical Risk Management. This research builds upon findings from a study investigating the clinical and real-world outcomes of Acthar Gel treatment in a subgroup of African Americans with symptomatic sarcoidosis, previously presented at the 2022 American Thoracic Society Annual International Conference in San Francisco and published in Therapeutic Advances in Respiratory Disease in 2019. Acthar is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides. Acthar Gel is approved by the FDA for the treatment of several autoimmune disorders and medical conditions known to cause inflammation, including symptomatic sarcoidosis.

06:57 EDT National Fuel reports preliminary voting results from Annual Meeting - National Fuel Gas Company announced the preliminary results of the stockholder vote on four management proposals as presented during the Annual Meeting of Stockholders, which was held March 8, 2024. All were approved, including the election of David H. Anderson, David P. Bauer, Barbara M. Bauman, David C. Carroll, Steven C. Finch, Joseph N. Jaggers, Rebecca Ranich, Jeffrey W. Shaw, Thomas E. Skains, David F. Smith and Ronald J. Tanski as directors for one-year terms expiring in 2025; the advisory vote on named executive officer compensation; the amended and restated equity compensation plan; and the ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm.

06:55 EDT Enservco announces recent dismissal of class action litigation - Enservco Corporation provided a business update. The company said, "The Company recorded solid full year operational performance for 2023 that will be reported later this month. In addition, Enservco has seen a strong start to 2024. The Company further commented on the recent receipt of notice from the U.S. District Court for the District of Colorado that an order to dismiss the pending class action lawsuit against the Company and certain of its representatives has been issued. In addition, as part of Enservco's focus on further elevating its investor relations efforts, the Company has engaged the services of Al Petrie Advisors. The firm is well known for their expertise in facilitating clear and impactful communication between companies and investors within the energy space." Rich Murphy, Chairman and CEO of Enservco, commented, "We ended 2023 with improvements both operationally and financially. Entering 2024, we are optimistic that our hard work will continue to yield good results. We are off to a strong start with our revenue for the first two months of 2024 coming in 15% higher than the same period in 2023. We are also pleased with the dismissal of the class action litigation. We now look forward to focusing all efforts on the many internal and external growth initiatives we are evaluating to enhance our asset position and drive long-term value for shareholders. We look forward to keeping everyone apprised of our progress."

06:53 EDT NFI Group's New Flyer awarded two contracts for up to 2,090 Xcelsior buses - New Flyer of America announced that it has been awarded two new contracts from the New York City Transit Authority including firm orders for 429 Xcelsior buses with options to purchase up to 1,661 additional buses over the next five years. In total, the two contracts add 3,050 EUs to NFI's first quarter 2024 backlog, including: A firm order for 187 battery-electric Xcelsior CHARGE NG 40-foot buses, with 943 additional options available. A firm order for 18 battery-electric Xcelsior CHARGE NG 60-foot buses, with 272 additional options available. A firm order for 224 Xcelsior 60-foot clean diesel buses, with 446 additional options available.

06:49 EDT Sam Edelman unveils Spring/Summer 2024 campaign featuring Kylie Jenner - Sam Edelman unveils its Spring/Summer 2024 campaign featuring Kylie Jenner. This seminal campaign marks the start of the Sam Edelman brand's 20th anniversary celebration taking place throughout the year.

06:41 EDT EQT Corporation to acquire Equitrans Midstream in all-stock transaction - EQT Corporation (EQT) and Equitrans Midstream (ETRN) announced that they have entered into a definitive merger agreement creating a vertically integrated natural gas business, with an initial enterprise value over $35B. Under the terms of the merger agreement, unanimously approved by the boards of both companies, EQT will acquire Equitrans in an all-stock transaction. Each outstanding share of Equitrans common stock will be exchanged for 0.3504 shares of EQT common stock, representing an implied value of $12.50 per Equitrans share based on the volume weighted average price of EQT common stock for the 30 days ending on March 8. As a result of the transaction, EQT's existing shareholders are expected to own approximately 74% of the combined company and Equitrans' shareholders are expected to own approximately 26%. The transaction is expected to close during the fourth quarter of 2024, subject to required regulatory approvals and clearances, approval of the transaction by shareholders of both EQT and Equitrans, and other customary closing conditions. The transaction closing is contingent on FERC authorizing MVP to commence service. Upon the closing of the transaction, three representatives from Equitrans will join EQT's board of directors. EQT's executive management team will lead the combined company with headquarters remaining in Pittsburgh, Pennsylvania.

06:38 EDT Choice provides update on Wyndham proposal, increases share repurchase program - Choice Hotels (CHH) announced the expiration of the exchange offer to acquire all of the issued and outstanding shares of Wyndham Hotels & Resorts (WH). The company is also withdrawing its nomination of the independent director candidates for election at Wyndham's 2024 annual meeting of stockholders. The company further announced that its board of directors has approved an increase in the number of shares authorized under its share repurchase program by 5M shares. When added to the remaining number of available shares previously authorized for repurchase, this results in a total authorization of approximately 6.8M shares. The company issued the following statement: "Since beginning this process in April 2023, Choice has attempted to engage in good-faith negotiations with Wyndham through numerous different avenues, including increasing the proposed offer multiple times and expressing an openness to further enhancing the offer with due diligence, offering a one-way NDA to share its confidential information with Wyndham, and offering above-market regulatory protections. Given Wyndham's refusal to constructively and substantively engage on terms, Choice took the extraordinary step of launching the exchange offer to initiate the regulatory review process and engage with Wyndham stockholders. While the support from Wyndham stockholders tendering into the exchange offer was significant considering the number of investors structurally prevented from participating at this stage, it was not sufficient for Choice to conclude - particularly when taking into account the Wyndham board's obvious continuing disinterest in a combination - that a path towards a transaction is available at this time. As such, Choice has decided not to extend the exchange offer and is withdrawing its slate. Choice intends to continue focusing on its standalone strategy, which the Company is confident will create significant long-term value for its stockholders and franchisees. Choice has a long history of delivering above average returns, is excited by the significant runway for growth grounded in its current business strategy and has always been disciplined in how it allocates capital. Choice's Board of Directors and management team are enthusiastic about the Company's go-forward strategy, which is expected to deliver another year of superior growth with projected adjusted EBITDA increasing approximately 10% at the midpoint of guidance, driven by: Choice's unique revenue intense strategy delivering accelerated unit growth and higher royalty revenue per hotel. Choice's continued realization of the higher-than-expected synergies resulting from the Radisson Americas business integration. Choice's platform earnings potential, highlighted by the significant outperformance of the co-brand credit card program launched in April. Choice's continued international business earnings growth and global pipeline expansion. The progress made on the regulatory front confirmed Choice's belief that the combination is pro-competitive, and approval would have been achievable in a customary timeframe. Choice thanks the stockholders and franchisees from both companies for their significant support in this process. Choice also thanks the independent director candidates it nominated for their time, effort and commitment to act in the best interests of the Wyndham stockholders. The exchange offer expired on March 8, 2024. No shares of Wyndham stock were purchased by WH Acquisition Corporation, a wholly owned subsidiary of Choice, pursuant to the exchange offer. Choice decided not to accept any shares pursuant to the offer due to a number of factors, including the refusal of the Wyndham board to engage in constructive discussions on terms and the fact that a number of the conditions to the offer, such as the minimum tender condition, remained unsatisfied as of the expiration date. Choice has instructed the exchange agent for the exchange offer to promptly return all tendered shares of Wyndham stock to the tendering stockholders."

06:32 EDT Fortrea to divest Endpoint Clinical, Fortrea Patient Access to Arsenal Capital - Fortre has signed a definitive agreement to divest assets relating to its Enabling Services segment, namely its Endpoint Clinical and Fortrea Patient Access businesses, to Arsenal Capital Partners. By divesting these businesses, Fortrea aims to advance the growth strategy and solutions of Endpoint and Fortrea Patient Access, positioning them for increased investment to accelerate the technology roadmap and further enhance operations to support best-in-class customer solutions and delivery. The remaining business of Fortrea will strengthen its focus on clinical development phases 1 through 4. Closing is targeted for the second quarter of 2024, subject to customary closing conditions and regulatory approvals, as well as the parties entering into certain services and operating agreements.

06:09 EDT MannKind announces initial meal challenge data from INHALE-3 study - MannKind Corporation announced initial meal challenge data from INHALE-3 that was presented by Dr. Irl B. Hirsch at the 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence on March 8th. INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin vs. standard of care. The statistically significant findings included: Subjects utilizing inhaled insulin experienced significantly reduced post-meal hyperglycemia, compared with those who used subcutaneous rapid-acting analogues delivered by MDI or pumps; Area under the curve was reduced by 20%; Inhaled insulin subjects demonstrated significantly lower glucose excursions from baseline; Mean glucose excursions were reduced by 22%; In the inhaled insulin group, mean glucose levels peaked 15 minutes sooner than in the standard of care group despite inhaled insulin being given at start of the meal vs. RAA being administered 5-15 minutes prior to the meal. The 17-week endpoint results from INHALE-3 will be presented Saturday, June 22, during a symposium at the American Diabetes Association's 84th Scientific Sessions in Orlando. INHALE-3 is a 17-week randomized controlled trial with a 13-week extension. The study, which enrolled 141 patient, assigned participants over 18 years of age with T1D who are using MDI, an automated insulin delivery system, or a pump without automation to either continue their standard of care or initiate an insulin regimen of a daily basal injection plus Afrezza for boluses. Subjects utilizing inhaled insulin received a higher initial conversion dose than in the current label. Both arms utilized continuous glucose monitoring to assess glucose control. A1c levels were obtained at baseline, 17 and 30-weeks. For the meal challenge, the inhaled insulin group took an inhaled insulin dose immediately prior to a standardized meal whereas those using usual care used RAA 5-15 minutes prior to the meal.

06:06 EDT International Petroleum announces results of normal course issuer bid - International Petroleum announced that IPC repurchased a total of 147,200 IPC common shares during the period of March 4 to 8, 2024 under IPC's normal course issuer bid / share repurchase program. IPC's NCIB, announced on December 1, 2023, is being implemented in accordance with the Market Abuse Regulation No 596/2014 and Commission Delegated Regulation No 2016/1052 and the applicable rules and policies of the Toronto Stock Exchange and Nasdaq Stockholm and applicable Canadian and Swedish securities laws. During the period of March 4 to 8, 2024, IPC repurchased a total of 105,000 IPC common shares on Nasdaq Stockholm. All of these share repurchases were carried out by Pareto Securities AB on behalf of IPC.

05:29 EDT NanoString to be acquired by Patient Square Capital for $220M - NanoString announced that it has reached an agreement with Patient Square Capital, a prominent health care investment firm, pursuant to which Patient Square will serve as the "stalking horse" bidder in conjunction with a court-supervised sales process. Under the terms of the agreement, Patient Square intends to purchase substantially all assets of the company's global business operations as a going concern for $220M. The agreement is part of a sale process under Section 363 of the Bankruptcy Code that will be subject to compliance with agreed upon and Bankruptcy Court-approved bidding procedures allowing for the submission of higher or otherwise better offers. In addition, the transaction is subject to Bankruptcy Court approval and customary closing conditions, including the expiration of the 15-day waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. A court hearing to approve the stalking horse bid and bidding procedures will take place on March 28. The company is requesting that the deadline for competing offers be set for 5 PM ET on April 12 and that a hearing to approve the sale take place on April 22.

05:18 EDT Newmark opens new office in Paris - Newmark announced it has established a Paris, France flagship. As the latest milestone in Newmark's continued global expansion, the Paris office, which officially opened, will initially focus on capital markets and leasing and is located at 32 Boulevard Haussmann 75009 Paris in the 9th arrondissement.

05:10 EDT Recursion Pharmaceuticals to open new office in London in June - Recursion announced plans to open a new office in London's King's Cross neighborhood. Set to formally open in June, the site will provide Recursion and Valence Labs, the company's artificial intelligence research engine, access to world-class talent across Europe's rapidly growing TechBio sector and embed Recursion in a thriving innovation ecosystem of leading technology and life science companies. Recursion's 6,700 square foot London office will be located at 3 Pancras Square, King's Cross London. The building is part of a 67-acre redevelopment project in King's Cross, with over 4.5M square feet of office space.